If you searched "another name for Enhertu," the answer is fam-trastuzumab deruxtecan — abbreviated T-DXd — the generic name of a medicine better known by its brand name Enhertu (优赫得 in China). Enhertu is a HER2-directed antibody-drug conjugate (ADC) given as an intravenous infusion, and the 100 mg refers to the single-dose vial strength, not an oral tablet. GLT supplies the Enhertu (fam-trastuzumab deruxtecan) 100 mg vial, the China-approved presentation from Daiichi Sankyo and AstraZeneca, on an inquiry basis with an indicative price of around $1,200 per vial.
What Is Enhertu?
Enhertu is an antibody-drug conjugate (ADC), a newer class of cancer medicine that links a targeting antibody to a cell-killing chemotherapy payload. The antibody part is a HER2-directed monoclonal antibody (trastuzumab), and the payload is a topoisomerase I inhibitor (deruxtecan) — which is exactly where the generic name fam-trastuzumab deruxtecan comes from. The "fam-" prefix denotes the FDA's naming convention for a family of trastuzumab derivatives.
The drug was jointly developed by Daiichi Sankyo (Japan) and AstraZeneca, and it has transformed the treatment of HER2-driven cancers — not only HER2-positive breast cancer, but also HER2-low breast cancer, gastric cancer, lung cancer, and, most recently, a broad "tumor-agnostic" solid-tumor indication. Its defining feature is a highly potent payload with a cleavable linker and a high drug-to-antibody ratio, which lets it kill neighboring cancer cells even when they express only low levels of HER2.
Enhertu Generic Name: Fam-Trastuzumab Deruxtecan (T-DXd)
The Enhertu generic name question trips up a lot of people, so it is worth being precise. Enhertu is the brand name; the generic (INN) name is fam-trastuzumab deruxtecan. In the United States the FDA adds a four-letter suffix, giving fam-trastuzumab deruxtecan-nxki, which is the same molecule. The Chinese generic name is 注射用德曲妥珠单抗 (trastuzumab deruxtecan for injection).
The abbreviation T-DXd is shorthand for "trastuzumab deruxtecan," and it is widely used in oncology literature. So if you see "another name for Enhertu," "Enhertu generic name," or "T-DXd," they all point to the same medicine: fam-trastuzumab deruxtecan. It should not be confused with ado-trastuzumab emtansine (T-DM1, Kadcyla) — a different HER2 ADC with a different linker and payload, also used in breast cancer.
Enhertu 100 mg: How It Is Supplied and Given
This is the most important practical point to get right: Enhertu is not a pill. The "100 mg" refers to a 100 mg single-dose vial of lyophilized (freeze-dried) powder that is reconstituted and given as an intravenous (IV) infusion by a healthcare professional — it is never taken by mouth. Each box contains one 100 mg vial.
The dose is calculated by body weight at 5.4 mg/kg, infused once every three weeks (a 21-day cycle). Because a single vial contains 100 mg, most adults need more than one vial per infusion — for example, a 70 kg patient requires about 378 mg, or roughly four vials, per dose. This is why the cost of Enhertu is usually discussed per vial and per treatment cycle, not per tablet. Infusion-related reactions are managed with pre-medication, and the infusion may be slowed or stopped if a reaction occurs.
What Is Enhertu Used For?
Enhertu has one of the broadest labels of any HER2-directed therapy. In China, its approved indications have expanded steadily since the first approval:
- HER2-positive metastatic breast cancer — the first Chinese approval, in February 2023, for later-line treatment.
- HER2-low metastatic breast cancer — extending benefit to patients previously classified as HER2-negative.
- HER2-positive gastric or gastroesophageal junction adenocarcinoma — a second-line option after trastuzumab-based therapy.
- HER2-mutant non-small cell lung cancer — for the roughly 2–4% of NSCLC driven by a HER2 mutation.
- HER2-positive early breast cancer — as neoadjuvant and, most recently, adjuvant treatment (September 2026).
- HER2-expressing (IHC 3+) advanced solid tumors — a tumor-agnostic approval in October 2026, the first of its kind for a HER2 ADC in China.
What makes Enhertu distinctive is that it works across both "HER2-positive" and "HER2-low" disease, and now across tumor types based on HER2 expression rather than on where the cancer started. Testing for HER2 expression is therefore the gateway to treatment — a detail any buyer should confirm with their oncologist before sourcing.
How Well Does It Work?
The approval is built on the DESTINY trial program, and the results are among the strongest ever reported in HER2-driven cancers. In HER2-positive metastatic breast cancer (DESTINY-Breast03), Enhertu roughly doubled progression-free survival compared with the previous standard T-DM1. In HER2-low metastatic breast cancer (DESTINY-Breast04), it became the first therapy to show a survival benefit in that previously underserved group. In HER2-mutant lung cancer (DESTINY-Lung02), it produced high response rates in a subgroup with historically poor outcomes.
For context, the numbers clinicians cite most often: in HER2-low breast cancer, Enhertu reduced the risk of disease progression or death by roughly half versus chemotherapy; in early-stage HER2-positive breast cancer with residual disease after neoadjuvant therapy (DESTINY-Breast05), it reduced the risk of invasive recurrence or death by 53% compared with T-DM1. These are practice-changing results that explain why Enhertu has become a standard across multiple lines and tumor types.
Safety: The Boxed Warnings
Enhertu is a powerful medicine with serious, potentially fatal side effects that require careful monitoring. The prescribing information carries a boxed warning for interstitial lung disease (ILD) / pneumonitis — the most important risk, which can be fatal. Patients are monitored for new or worsening cough, breathlessness or fever, and treatment is withheld or discontinued if ILD is suspected.
Other key warnings include neutropenia (low white blood cell counts, checked before each dose), left ventricular dysfunction (heart function is assessed before and during treatment), and embryo-fetal toxicity (contraception is required during treatment and for months after the last dose). Nausea and vomiting are common and are managed with pre-medication before each infusion. Because of these requirements, Enhertu is administered only under the supervision of an oncology team experienced with ADCs.
Fam Trastuzumab Deruxtecan Price and Where to Buy
Cost matters because Enhertu is given repeatedly — one infusion every three weeks, often for many months. GLT supplies the China-approved Enhertu (fam-trastuzumab deruxtecan) 100 mg vial at an indicative around $1,200 per 100 mg vial. Because the dose is 5.4 mg/kg, a full infusion typically uses several vials, so buyers should budget per treatment cycle rather than per vial.
Enhertu is a prescription oncology medicine with a boxed warning, so GLT follows an inquiry process rather than a self-service cart:
- Confirm the HER2 status (positive, low, or IHC 3+ expression) and the treatment line with your oncologist.
- Send your inquiry via WhatsApp or email with the number of 100 mg vials you need.
- Our team verifies availability and batch details, then arranges cold-chain dispatch with appropriate storage.
Questions or ready to order? Contact us on WhatsApp +86 15234153837 or email [email protected].
Frequently Asked Questions
What is another name for Enhertu?
Enhertu's generic name is fam-trastuzumab deruxtecan, abbreviated T-DXd. In the US it is written fam-trastuzumab deruxtecan-nxki; in China the generic name is 注射用德曲妥珠单抗 (trastuzumab deruxtecan for injection).
What is the generic name of Enhertu?
The generic name of Enhertu is fam-trastuzumab deruxtecan (T-DXd). It is a HER2-directed antibody-drug conjugate developed by Daiichi Sankyo and AstraZeneca.
Is Enhertu a pill or an injection?
Enhertu is an intravenous (IV) infusion, not a pill. The 100 mg strength refers to a single-dose vial of freeze-dried powder that is reconstituted and infused into a vein once every three weeks.
What is Enhertu 100 mg used for?
Enhertu is used for HER2-positive and HER2-low breast cancer, HER2-positive gastric cancer, HER2-mutant lung cancer, HER2-positive early breast cancer, and HER2-expressing (IHC 3+) advanced solid tumors.
How much does fam-trastuzumab deruxtecan cost?
GLT's indicative price is around $1,200 per 100 mg vial of the China-approved Enhertu. Because dosing is 5.4 mg/kg every three weeks, a full infusion usually uses multiple vials. Contact GLT for a current quote.
Is Enhertu the same as Kadcyla (T-DM1)?
No. Both are HER2-directed ADCs, but Enhertu is fam-trastuzumab deruxtecan (T-DXd), while Kadcyla is ado-trastuzumab emtansine (T-DM1). They have different linkers and chemotherapy payloads.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Enhertu (fam-trastuzumab deruxtecan / 优赫得) is a prescription oncology medicine with a boxed warning; always consult a qualified oncologist about diagnosis, HER2 testing, dosing, and treatment. Prices are indicative and subject to confirmation at inquiry.